^
Association details:
| Biomarker: | AXL-L |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + dubermatinib (TP-0903) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1075 - AXL is a potential druggable target in trastuzumab resistance in HER2+ breast cancer patients
Published date:
03/10/2021
Excerpt:
The prognostic value of AXL was evaluated in primary tumor cohort of HER2+ BC patients...The median DFS and OS were 36 and 77 months in patients with high AXL level, whereas patients with low AXL level presented 92.5 and 92.5 months.
